EUVIMEDEUVIMED entdecken
Systematische Übersicht

Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia

Arturo Vega-Beyhart iD, Betina Biagetti iD, Mónica Marazuela iD, Manel Puig-Domingo iD, Marta Araujo-Castro iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf195 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Arturo Vega-Beyhart und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain. Hauptthemen laut MEDLINE: Somatostatin, Hypoglycemia, Insulinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Persistent hypoglycemia is a life-threatening complication in insulinoma patients. When tumor excision is not possible, medical treatments are the main option. Pasireotide has shown promise in managing refractory hypoglycemia, but its use has been reported only in case series and reports.

Objective

This work aimed to assess the efficacy and safety of pasireotide in treating insulinoma-associated hypoglycemia.

Methods

We conducted a systematic review on using pasireotide to treat insulinoma-associated hypoglycemia, following a predeveloped protocol. We searched MEDLINE, Scopus, Google Scholar, and references forward and backward from database inception to March 30, 2024.

Results

Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria. Patients' ages ranged from 52 to 71 years (9 women). Five patients (30%) underwent surgical tumor resection. Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3).

Conclusion

Pasireotide effectively restored glucose levels in insulinoma patients who failed prior treatments. However, its efficacy was lower in aggressive insulinomas, emphasizing the need for alternative or combinatory strategies in metastatic cases. Given that pasireotide was never used as a first-line therapy in the reviewed cases, earlier administration in selected patients may improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SomatostatinHypoglycemiaInsulinomaPancreatic NeoplasmsHumansMiddle AgedFemaleAgedMaleTreatment Outcome

Stichwörter der Autor:innen

SOM230hypoglycemiainsulinomapasireotide

Substanzen

pasireotideSomatostatin

Autor:innen und Institutionen

  • Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario Vall d'Hebrón, 08032 Barcelona, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitario La Princesa, 28006 Madrid, Spain.
  • Endocrinology & Nutrition Department, Hospital Universitari i Institut de Recerca Germans Trias i Pujol, 08916 Badalona, Spain.

ORCID-Profile: Arturo Vega-Beyhart, Betina Biagetti, Mónica Marazuela, Manel Puig-Domingo, Marta Araujo-Castro

Zitieren

APA

Vega-Beyhart, A., Biagetti, B., Marazuela, M., Puig-Domingo, M., & Araujo-Castro, M. (2025). Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf195

Vancouver

Vega-Beyhart A, Biagetti B, Marazuela M, Puig-Domingo M, Araujo-Castro M. Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf195

BibTeX
@article{VegaBeyhart2025,
  author = {Vega-Beyhart, Arturo and Biagetti, Betina and Marazuela, Mónica and Puig-Domingo, Manel and Araujo-Castro, Marta},
  title = {Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf195}
}
Kostenlos starten →